Zacks: Protalix BioTherapeutics Inc. (PLX) Receives Average Rating of “Strong Buy” from Analysts
Protalix BioTherapeutics Inc. (NYSE:PLX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $2.15 for the company and are forecasting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Protalix BioTherapeutics an industry rank of 109 out of 265 based on the ratings given to related companies.
PLX has been the topic of a number of recent research reports. Rodman & Renshaw reissued a “buy” rating on shares of Protalix BioTherapeutics in a research report on Monday, July 11th. Zacks Investment Research lowered Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Finally, Jefferies Group dropped their target price on Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating on the stock in a research report on Tuesday, September 6th.
Protalix BioTherapeutics (NYSE:PLX) opened at 0.5081 on Friday. Protalix BioTherapeutics has a one year low of $0.49 and a one year high of $1.25. The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $0.70. The firm has a market capitalization of $50.69 million and a price-to-earnings ratio of 1.0042.
Protalix BioTherapeutics (NYSE:PLX) last announced its earnings results on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. The company earned $1.77 million during the quarter, compared to analyst estimates of $1.34 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. On average, equities research analysts expect that Protalix BioTherapeutics will post ($0.41) EPS for the current fiscal year.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.